InSilico Medicine Cayman TopCo Forecast, price target & analysts
Why the stock moved Beta
InSilico Medicine Cayman TopCo Target price 2026 - Analyst rating & recommendation
InSilico Medicine Cayman TopCo Classifications & Recommendation
InSilico Medicine Cayman TopCo Price Target
| Target Price | HK$78.54 |
| Price | HK$53.75 |
| Potential |
46.12%
register free of charge
|
| Number of Estimates | 8 |
|
8 Analysts have issued a price target InSilico Medicine Cayman TopCo 2027 .
The average InSilico Medicine Cayman TopCo target price is HK$78.54.
This is
46.12%
register free of charge
HK$105.00
95.35%
register free of charge
HK$74.74
39.05%
register free of charge
|
|
| A rating was issued by 14 analysts: 13 Analysts recommend InSilico Medicine Cayman TopCo to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the InSilico Medicine Cayman TopCo stock has an average upside potential 2027 of
46.12%
register free of charge
|
Sales and Margin forecast 2026, 2027 & 2028
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million HK$ | 441.17 | 1,436.90 |
| 34.48% | 225.70% | |
| EBITDA Margin | -92.54% | -0.17% |
| 192.17% | 99.82% | |
| Net Margin | -626.47% | -3.59% |
| 3,045.32% | 99.43% |
10 Analysts have issued a sales forecast InSilico Medicine Cayman TopCo 2026 . The average InSilico Medicine Cayman TopCo sales estimate is
This results in the following potential growth metrics:
8 Analysts have issued an InSilico Medicine Cayman TopCo EBITDA forecast 2026. The average InSilico Medicine Cayman TopCo EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
10 InSilico Medicine Cayman TopCo Analysts have issued a net profit forecast 2026. The average InSilico Medicine Cayman TopCo net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 & 2028
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share HK$ | -4.96 | -0.09 |
| 1,966.67% | 98.19% | |
| P/E | negative | |
| EV/Sales | 18.13 |
10 Analysts have issued a InSilico Medicine Cayman TopCo forecast for earnings per share. The average InSilico Medicine Cayman TopCo EPS is
This results in the following potential growth metrics and future valuations:
InSilico Medicine Cayman TopCo...
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
